
Gain Therapeutics, Inc.: updates and filings
Price
$1.00
November 20, 2026Market cap $44M
What Ploutos Investor adds for Gain Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Other material eventsForm8-K
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 28, 2026Officer or director changeForm8-K
- Oct 1, 2026Other material eventsForm8-K
- Sep 28, 2026Officer or director changeForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 16, 2026Other material eventsForm8-K
- Jun 29, 2026Other material eventsForm8-K
- Jun 25, 2026Shareholder voteForm8-K
- May 26, 2026Other material eventsForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 26, 2026Results of operationsForm8-K
- Mar 18, 2026Regulation FD disclosure, other material eventsForm8-K
- Feb 3, 2026Regulation FD disclosureForm8-K
- Dec 18, 2025Other material eventsForm8-K
- Dec 3, 2025Shares registered for employeesFormS-8
- Nov 28, 2025Other material eventsForm8-K
- Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | 8-K | Other material events | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 28, 2026 | 8-K | Officer or director change | Document |
| Oct 1, 2026 | 8-K | Other material events | Document |
| Sep 28, 2026 | 8-K | Officer or director change | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 16, 2026 | 8-K | Other material events | Document |
| Jun 29, 2026 | 8-K | Other material events | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| May 26, 2026 | 8-K | Other material events | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 26, 2026 | 8-K | Results of operations | Document |
| Mar 18, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Feb 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Dec 18, 2025 | 8-K | Other material events | Document |
| Dec 3, 2025 | S-8 | Shares registered for employees | Document |
| Nov 28, 2025 | 8-K | Other material events | Document |
| Nov 12, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 30, 2020.
The full analysis
What do Gain Therapeutics's filings show?
The filings are where every one of Gain Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.